02359 News
CLSA Assigns HKD143.4 Target Price to WUXI APPTEC; Quarterly Results Surpass Expectations, Performance Expected to Outpace Market This Year
CLSA Identifies WUXI APPTEC (02359.HK) as a Leading Choice in China's Pharma CRO/CDMO Sectors, Anticipating Superior Performance This Year
JPM: WUXI APPTEC Issues Strong Profit Forecast; Market Expected to Respond Favorably
M Stanley Maintains WUXI APPTEC as 2026 Top Choice Following Over 100% Earnings Growth in 2025
Nomura Reports WUXI APPTEC (02359.HK) Exceeds Expectations in 4Q25; Anticipates Continued Growth This Year
WUXI APPTEC Rises Over 6% Amid Anticipated ~103% Year-Over-Year Increase in 2025 Net Profit
WUXI APPTEC Anticipates Approximately 103% Year-Over-Year Growth in 2025 Net Profit
M Stanley Publishes Thematic Focus List for Asia Pacific – Top Conviction Opportunities (Table)
02359 Events
No data
02359 Monitor News
No data
02359 Earnings Analysis